0.00
100.00%
-29.80
After Hours:
29.00
29.00
+
PureTech Health Plc ADR stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $29.49 pivot point. If it approaches the $28.27 support level, significant changes may occur.
Previous Close:
$29.80
Open:
$0
24h Volume:
0
Market Cap:
$807.03M
Revenue:
$1.70M
Net Income/Loss:
$-47.01M
P/E Ratio:
0.00
EPS:
-1.7
Net Cash Flow:
$-157.28M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
+0.00%
PureTech Health Plc ADR Stock (PRTC) Company Profile
Name
PureTech Health Plc ADR
Sector
Industry
Phone
617 482 2333
Address
6 Tide Street, Suite 400, Boston
PureTech Health Plc ADR Stock (PRTC) Latest News
2024-05-23 | NDAQ:PRTC | Press Release | PureTech Health ADR Representing 10 Ord Shs - Stockhouse Publishing
Stockhouse Publishing
2024-05-23 | NDAQ:PRTC | Press Release | PureTech Health ADR Representing 10 Ord Shs - Stockhouse Publishing
Stockhouse Publishing
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - Business Wire
Business Wire
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - Business Wire
Business Wire
Wall Street Analysts Predict an 82% Upside in PureTech Health PLC Sponsored ADR (PRTC): Here's What You ... - Yahoo News UK
Yahoo News UK
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research
PureTech Health Plc ADR Stock (PRTC) Financials Data
PureTech Health Plc ADR (PRTC) Revenue 2024
PRTC reported a revenue (TTM) of $1.70 million for the quarter ending June 30, 2023, a -67.74% decline year-over-year.
PureTech Health Plc ADR (PRTC) Net Income 2024
PRTC net income (TTM) was -$47.01 million for the quarter ending June 30, 2023, a +75.69% increase year-over-year.
PureTech Health Plc ADR (PRTC) Cash Flow 2024
PRTC recorded a free cash flow (TTM) of -$157.28 million for the quarter ending June 30, 2023, a -6.85% decrease year-over-year.
PureTech Health Plc ADR (PRTC) Earnings per Share 2024
PRTC earnings per share (TTM) was -$1.70 for the quarter ending June 30, 2023, a +74.63% growth year-over-year.
About PureTech Health Plc ADR
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):